Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
11 participants
INTERVENTIONAL
2020-06-01
2020-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pilocarpine and Brimonidine in Patients With Monofocal Lenses
NCT03825081
A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia
NCT03201562
Phase 3 Efficacy Study of LNZ101 for the Treatment of Presbyopia
NCT05728944
Safety & Efficacy of Pilocarpine Ophthalmic Spray for Temporary Improvement of Near Vision in Presbyopic Adults
NCT05114486
Safety & Efficacy of Pilocarpine Eye Solutions for Temporary Improvement of Near Vision in Presbyopic Adults
NCT04657172
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PBO Investigational drug
Pilocarpine, brimonidine, oxymetazoline combined with hyaluronic acid and bromfenac combined in an ophthalmic solution to be randomly instilled in one eye.
PBO to control presbyopia symptoms
Low dose PBO to control presbyopia symptoms
Pilocarpine
Pilocarpine was instilled in the other oye.
PBO to control presbyopia symptoms
Low dose PBO to control presbyopia symptoms
Brimonidine
Brimonidine was instilled in the other eye.
PBO to control presbyopia symptoms
Low dose PBO to control presbyopia symptoms
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PBO to control presbyopia symptoms
Low dose PBO to control presbyopia symptoms
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Presbyopic
* 40 - 59 years
Exclusion Criteria
* Previous eye surgery
* Previous eye disease
* \> 0.50 myopia
* \> 1.5 hyperopia or astigmatism
40 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Optall Vision
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cesar Alejandro Sanchez Galeana
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cesar Alejandro S Galeana
Role: PRINCIPAL_INVESTIGATOR
Optall Vision
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Optall Vision
Mexico City, , Mexico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PBOPC01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.